00:00Finally, we have a therapeutic novelty. Most of the effective therapies for psoriasis
00:12have been injective therapies, monoclonal antibodies, so-called biological drugs. Finally,
00:17a small molecule arrives that can be taken by mouth once a day, which interferes
00:24precisely with the mechanisms that lead to the development of plaques. And how does it work?
00:29It binds to a protein that is inside the cells and that has the task of signaling inflammation.
00:35So, by blocking this protein, it blocks the inflammation signal in the skin of our patients.
00:42And what happens? It happens that over the course of weeks, the patient sees his skin improve
00:49and, in concomitance, he sees his quality of life improve, because the pluritus disappears,
00:55the visible plaques disappear. This molecule, which has finally been approved and also
01:02reimbursed in Italy through the National Health Service, has been tested in clinical studies
01:09against another oral molecule, called Premilast, which has worked less. So,
01:15Deucravacitinib works about 20-30% more than Premilast. It induces the healing of
01:25psoriasis plaques in more than 60% of our patients. So, it is used for those patients
01:32who have a severe moderate disease, failure or contraindication of conventional therapies
01:40such as cyclosporine and methotrexate, and on a large number of patients affected by this disease.
01:48So far, the data we have tell us that as long as you take Deucravacitinib,
01:54as long as you take this compress every day, psoriasis remains under control.
01:59With suspension, psoriasis can return, of course, because it is a chronic disease,
02:04on a genetic basis, but it returns very slowly, so there is always time to restart the therapy.
02:12The indication, at the moment, is to take it chronically.
Comments